| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Tris(2-cyanoethyl)phosphine does not target a specific protein or enzyme as a pharmacological agent. Its utility in biological research is based on its chemical reactivity, particularly its reducing properties that convert disulfides to thiols. This makes it valuable for peptide synthesis and protein modification, where it can reduce disulfide bonds without affecting other functional groups. The compound's phosphine group can also coordinate to metal ions, and it has been utilized to prepare copper(I) complexes with anti-tumor effects. However, these effects are due to the metal complexes rather than the compound itself.
|
|---|---|
| ln Vitro |
The in vitro activity of tris(2-cyanoethyl)phosphine is primarily as a reducing agent for disulfide bonds. It is used in peptide synthesis and protein modification to reduce disulfides to free thiols. The compound can also be used to produce 3,3',3''-phosphanetriyl-tri-propionic acid and hydrochloride by heating. As a protein cross-linker, it can form covalent links between proteins, facilitating studies of protein structure and interactions. The compound has been utilized to prepare copper(I) complexes with anti-tumor effects, suggesting potential applications in cancer research.
|
| ln Vivo |
No significant in vivo pharmacological activity has been reported for tris(2-cyanoethyl)phosphine itself, as the compound is primarily used as a chemical reagent. However, copper(I) complexes prepared using this compound have shown anti-tumor effects, indicating that derivatives may have in vivo activity. The compound's reducing properties could potentially affect biological systems if administered, but such applications are not documented.
|
| Enzyme Assay |
In vitro assays for tris(2-cyanoethyl)phosphine typically involve its use as a reducing agent in peptide synthesis. The compound is added to reaction mixtures containing disulfide-containing peptides or proteins, where it reduces disulfide bonds to free thiols. The reaction progress can be monitored by methods such as Ellman's assay for thiol detection or by HPLC analysis of the reduced products. The compound can also be used in cross-linking studies where it forms covalent links between proteins.
|
| Cell Assay |
For in vitro cellular experiments, tris(2-cyanoethyl)phosphine is not typically used directly in cell-based assays due to its reactivity and potential toxicity. However, it may be used in the preparation of protein samples for cellular studies, such as reducing disulfide bonds in proteins prior to analysis. The compound's utility in preparing copper(I) complexes with anti-tumor effects suggests that these complexes could be tested in cellular assays.
|
| Animal Protocol |
In vivo animal experiments with tris(2-cyanoethyl)phosphine are not commonly performed, as the compound is primarily used as a chemical reagent. Copper(I) complexes prepared using this compound have shown anti-tumor effects, suggesting that these derivatives could be tested in animal models of cancer. However, the compound itself is not intended for in vivo use.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of tris(2-cyanoethyl)phosphine have not been characterized, as the compound is a research-use chemical reagent rather than a drug candidate. The compound has a molecular weight of 193.19 g/mol and is a solid at room temperature with a melting point of 95.0 to 99.0°C. It should be stored at room temperature in a cool, dark place below 15°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for tris(2-cyanoethyl)phosphine has not been systematically evaluated for therapeutic use. The compound is classified as a Dangerous Good for transport and may be subject to additional shipping charges, indicating it has hazardous properties. It is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References |
[1]. Zanella A, et, al. Cytotoxicity in human cancer cells and mitochondrial dysfunction induced by a series of new copper(I) complexes containing tris(2-cyanoethyl)phosphines. Invest New Drugs. 2011 Dec;29(6):1213-23.
|
| Additional Infomation |
Tris(2-cyanoethyl)phosphine (CAS#: 4023-53-4) is a versatile organophosphorus compound used as a protein cross-linker and reducing agent for disulfides to thiols in peptide synthesis and modification. It is also used to prepare copper(I) complexes with anti-tumor effects. The compound has no clinical or therapeutic applications and has not received regulatory approval for any medical indication.
|
| Molecular Formula |
C9H12N3P
|
|---|---|
| Molecular Weight |
193.19
|
| Exact Mass |
193.077
|
| CAS # |
4023-53-4
|
| PubChem CID |
77639
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
235°C 0,9mm
|
| Melting Point |
97-98°C
|
| Flash Point |
235°C/0.9mm
|
| Vapour Pressure |
1.71E-07mmHg at 25°C
|
| LogP |
2.209
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
13
|
| Complexity |
223
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C#N)CP(CCC#N)CCC#N
|
| InChi Key |
CHZAMJVESILJGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H12N3P/c10-4-1-7-13(8-2-5-11)9-3-6-12/h1-3,7-9H2
|
| Chemical Name |
3-[bis(2-cyanoethyl)phosphanyl]propanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1763 mL | 25.8813 mL | 51.7625 mL | |
| 5 mM | 1.0353 mL | 5.1763 mL | 10.3525 mL | |
| 10 mM | 0.5176 mL | 2.5881 mL | 5.1763 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
